WJCD  Vol.4 No.3 , March 2014
Amiodarone Therapy for Cardiac Arrhythmias: Is It Associated with the Development of Cancers?

Amiodarone is used worldwide to treat cardiac arrhythmias, as well as highly symptomatic cases of atrial fibrillation. With this expanded use, especially following its 1985 United States Food and Drug Administration approval, and its use as a long-term therapy in common practice, reports of cancers temporarily related to amiodarone have begun to increase. Animal studies, several clinical trials, numerous case reports, and a population-based cohort study have suggested that cancers may be associated with amiodarone use. This review focuses on the ever increasing evidence in the literature that suggests amiodarone therapy, especially with long-term use, may increase the potential risk of cancer development. It also expresses the need for more definitive studies to be conducted to provide clinicians with a clear answer to this important question.

Cite this paper
Mali, P. , Henry Salzman, M. , Vidaillet, H. and Rezkalla, S. (2014) Amiodarone Therapy for Cardiac Arrhythmias: Is It Associated with the Development of Cancers?. World Journal of Cardiovascular Diseases, 4, 109-118. doi: 10.4236/wjcd.2014.43017.
[1]   Saad, A., Falciglia, M., Steward, D.L., and Nikiforov, Y.E. (2004) Amiodarone-Induced Thyrotoxicosis and Thyroid Cancer: Clinical, Immunohistochemical, and Molecular Genetic Studies of a Case and Review of the Literature. Archives of Pathology & Laboratory Medicine, 128, 807-810.

[2]   Piccini, J.P., Berger, J.S., and O’Connor, C.M. (2009) Amiodarone for the Prevention of Sudden Cardiac Death: A Meta-Analysis of Randomized Controlled Trials. European Heart Journal, 30, 1245-1253.

[3]   Papiris, S.A., Triantafillidou, C., Kolilekas, L., Markoulaki, D., and Manali, E.D. (2010) Amiodarone: Review of Pulmonary Effects and Toxicity. Drug Saf, 33, 539-558.

[4]   United States Food and Drug Administration (2004) Medication Guide: Amiodarone HCl. NDA18-972/S-038/039, Washington DC.

[5]   Julian, D.G., Camm, A.J., Frangin, G., Janse, M.J., Munoz, A., Schwartz, P.J. and Simon, P. (1997) Randomised Trial of Effect of Amiodarone on Mortality in Patients with Left-Ventricular Dysfunction after Recent Myocardial Infarction: EMIAT. Lancet, 349, 667-674.

[6]   Connolly, S.J. (1999) Evidence-Based Analysis of Amiodarone Efficacy and Safety. Circulation, 19, 2025-2034.

[7]   Hall, M.A., Annas, A., Nyman, K., Talme, T. and Emtestam, L. (2004) Basiloma after Amiodarone Therapy—Not Only in Britain. British Journal of Dermatology, 151, 932-933.

[8]   Siddoway, L.A. (2003) Amiodarone: Guidelines for Use and Monitoring. American Family Physician, 68, 2189-2196.

[9]   Wilkinson, C.M., Weidner, G.J. and Paulino, A.C. (2001) Amiodarone and Radiation Therapy Sequelae. American Journal of Clinical Oncology, 24, 379-381.

[10]   Ceremuzynski, L., Kleczar, E., Krzeminska-Pakula, M., Kuch, J., Nartowicz, E., Smielak-Korombel, J., et al. (1992) Effect of Amiodarone on Mortality after Myocardial Infarction: A Double-Blind, Placebo-Controlled, Pilot Study. Journal of the American College of Cardiology, 20, 1056-1062.

[11]   Brambilla, G. and Martelli, A. (2009) Update on Genotoxicity and Carcinogenicity Testing of 472 Marketed Pharmaceuticals. Mutation Research/Reviews in Mutation Research, 681, 209-229.

[12]   Hamer, A.W., Arkles, L.B. and Johns, J.A. (1989) Beneficial Effects of Low Dose Amiodarone in Patients with Congestive Cardiac Failure: A Placebo-Controlled Trial. Journal of the American College of Cardiology, 14, 1768 1774.

[13]   Cairns, J.A., Connolly, S.J., Roberts, R. and Gent, M. (1997) Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet, 349, 675-682.

[14]   Elizari, M.V., Martinez, J.M., Belziti, C., Ciruzzi, M., Perez de la Hoz, R., Sinisi, A., et al. (2000) Morbidity and Mortality Following Early Administration of Amiodarone in Acute Myocardial Infarction. European Heart Journal, 21, 198-205.

[15]   Roy, D., Talajic, M., Dorian, P., Connolly, S., Eisenberg, M.J., Green, M., et al. (2000) Amiodarone to Prevent Recurrence of Atrial Fibrillation. New England Journal of Medicine, 342, 913-920.

[16]   Batcher, E.L., Tang, X.C., Singh, B.N., Singh, S.N., Reda, D.J. and Hershman, J.M. (2007) Thyroid Function Abnormalities during Amiodarone Therapy for Persistent Atrial Fibrillation. The American Journal of Medicine, 120, 880-885.

[17]   Inaba, H., Suzuki, S., Takeda, T., Kobayashi, S., Akamizu, T. and Komatsu, M. (2012) Amiodarone-Induced Thyrotoxicosis with Thyroid Papillary Cancer in Multinodular Goiter: Case Report. Medical Principles and Practice, 21, 190-192.

[18]   Palermo-Garofalo, C., Martinez, J.H., Silva, F., Gonzalez, E., Torres, O., Figueroa, J., et al. (2013) The Cardiology and Endocrinology Connection between Amiodarone and Thyrotoxicosis: Case Report and Review of the Literature. Boletín de la Asociación Médica de Puerto Rico, 105, 47-53.

[19]   Danzi, S. and Klein. I. (2013) Amiodarone-Induced Thyroid Dysfunction. Journal of Intensive Care Medicine. (Epub ahead of print)

[20]   Pitsiavis, V., Smerdely, P., Li, M. and Boyages, S.C. (1997) Amiodarone Induces a Different Pattern of Ultrastructural Change in the Thyroid to Iodine Excess Alone in Both the BB/W Rat and the Wistar Rat. European Journal of Endocrinology, 137, 89-98.

[21]   Taneri, F., Kurukahvecioglu, O., Ege, B., Yilmaz, U., Tekin, E.H., Cifter, C. and Onuk, E. (2005) Clinical Presentation and Treatment of Hyperthyroidism Associated with Thyroid Cancer. Endocrine Regulations, 39, 91-96.

[22]   Mori, I., Miyauchi, A., Kuma, S., Tang, W. and Kakudo, K. (2003) Thyroid Nodular Lesion: Analysis of Cancer Risk Based on Kuma Hospital Experience. Pathology International, 53, 579-583.

[23]   Oertli, D., Harder, F., Oberholzer, M. and Staub, J.J. (1998) Hyperthyroidism and Thyroid Carcinoma—Coincidence or Association? Schweizerische medizinische Wochenschrift, 128, 1910-1914.

[24]   Cattaneo, F. (2000) Type II Amiodarone-Induced Thyrotoxicosis and Concomitant Papillary Cancer of the Thyroid. European Journal of Endocrinology, 143, 823-824.

[25]   Su, V.Y., Hu, Y.W., Chou, K.T., Ou, S.M., Lee, Y.C., Lin, E.Y., Chen, T.J., Tzeng, C.H. and Liu, C.J. (2013) Amiodarone and the Risk of Cancer: A National Population-Based Study. Cancer, 119, 1699-1705.

[26]   Bridges, A.B., Davies, R.R., Newton, R.W. and McNeill, G.P. (1989) Anaplastic Carcinoma of the Thyroid in a Patient Receiving Radio-Iodine Therapy for Amiodarone-Induced Thyrotoxicosis. Scottish Medical Journal, 34, 471-472.

[27]   Monk, B.E. (1995) Basal Cell Carcinoma Following Amiodarone Therapy. British Journal of Dermatology, 133, 148-149.

[28]   Maoz, K.B., Dvash, S., Brenner, S. and Brenner, S. (2009) Amiodarone-Induced Skin Pigmentation and Multiple Basal-Cell Carcinomas. International Journal of Dermatology, 48, 1398-1400.

[29]   Stahli, B.E. and Schwab, S. (2011) Amiodarone-Induced Skin Hyperpigmentation. QJM: An International Journal of Medicine, 104, 723-724.

[30]   Monk, B. (1990) Amiodarone-Induced Photosensitivity and Basal-Cell Carcinoma. Clinical and Experimental Dermatology, 15, 319-320.

[31]   Monk, B. (2004) Amiodarone and Basal Cell Carcinoma, Coincidence or Association? British Journal of Dermatology, 151, 933.

[32]   De Neve, W., Fortan, L. and Storme, G. (1992) Increased Acute Mucosal and Cutaneous Radiation Toxicity in Two Patients Taking Amiodarone. International Journal of Radiation Oncology, Biology, Physics, 22, 224.

[33]   Azzam, I., Tov, N., Elias, N. and Naschitz, J.E. (2006) Amiodarone Toxicity Presenting as Pulmonary Mass and Peripheral Neuropathy: The Continuing Diagnostic Challenge. Postgraduate Medical Journal, 82, 73-75.

[34]   Alsamri, M.T., Pramathan, T. and Souid, A.K. (2013) In Vitro Study on the Pulmonary Cytotoxicity of Amiodarone. Toxicology Mechanisms and Methods, 23, 610-616.

[35]   Patel, P., Honeybourne, D. and Watson, R.D. (1987) Amiodarone-Induced Pulmonary Toxicity Mimicking Metastatic Lung Disease. Postgraduate Medical Journal, 63, 393-394.

[36]   Arnon, R., Raz, I., Chajek-Shawl, T., Berkman, N., Fields, S. and Bar-On, H. (1988) Amiodarone Pulmonary Toxicity Presenting as a Solitary Lung Mass. Chest, 93, 425-427.

[37]   Piccione Jr., W., Faber, L.P. and Rosenberg, M.S. (1989) Amiodarone-Induced Pulmonary Mass. Annals of Thoracic Surgery, 47, 918-919.

[38]   Rodriguez-Garcia, J.L., Garcia-Nieto, J.C., Ballesta, F., Prieto, E., Vil-lanueva, M.A. and Gallardo, J. (2001) Pulmonary Mass and Multiple Lung Nodules Mimicking a Lung Neoplasm as Amiodarone-Induced Pulmonary Toxicity. European Journal of Internal Medicine, 12, 372-376.

[39]   Jarand, J., Lee, A. and Leigh, R. (2007) Amiodaronoma: An Unusual Form of Amiodarone-Induced Pulmonary Toxicity. Canadian Medical Association Journal, 176, 1411-1413.

[40]   Facchini, G., Forte, S., Podda, P., Piro, F. and Carlone, S. (2008) Pulmonary Masses in a Patient with Blue-Gray Cutaneous Hyperpigmentation. European Review for Medical and Pharmacological Sciences, 12, 113-116.

[41]   Kimura, T., Kuramochi, S., Katayama, T., Yoshikawa, T., Yamada, T., Ueda, Y. and Okada, Y. (2008) Amiodarone-Induced Pulmonary Mass and Unique Membranous Glomerulonephritis in a Patient with Valvular Heart Disease: Diagnostic Pitfall and New Findings. Pathology International, 58, 657-663.

[42]   Garg, J., Agrawal, N., Marballi, A., Agrawal, S., Rawat, N., Sule, S. and Lehrman, S.G. (2012) Amiodarone Induced Pulmonary Toxicity: An Unusual Response to Steroids. American Journal of Case Reports, 13, 62-65.

[43]   Araki, R., Yukawa, E., Nakashima, M.N., Fukuchi, H., Sasaki, H., Yano, K. and Nakashima, M. (2011) Population Pharmacokinetic Investigation for Optimization of Amiodarone Therapy in Japanese Patients. Therapeutic Drug Monitoring, 33, 750-756.